Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Tumors|Ovarian Cancer|Breast Cancer|Lung Cancer|Pancreatic Cancer
Interventions: DRUG: ZN-c3|DRUG: Bevacizumab|DRUG: Pembrolizumab
Sponsor: M.D. Anderson Cancer Center
Collaborators: Zentalis Pharmaceuticals